Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression

Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis

(2020) Natalie A. Schwehr et al.   DRUGS & AGING

Epidemiology and treatment of multiple sclerosis in elderly populations

(2019) Caila B. Vaughn et al.   Nature Reviews Neurology

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis

(2019) Wallace J Brownlee et al.   BRAIN

Plasma proteome in multiple sclerosis disease progression

(2019) Arjan Malekzadeh et al.   Annals of Clinical and Translational Neurology

Multiple Sclerosis

(2018) Daniel S. Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

(2017) Jan Fagius et al.   Multiple Sclerosis and Related Disorders

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials

(2015) A. Signori et al.   EUROPEAN JOURNAL OF NEUROLOGY

Optimizing treatment success in multiple sclerosis

(2015) Tjalf Ziemssen et al.   JOURNAL OF NEUROLOGY

Pathological mechanisms in progressive multiple sclerosis

(2015) Don H Mahad et al.   LANCET NEUROLOGY

Relapses and disability accumulation in progressive multiple sclerosis

(2014) M. M. Paz Soldan et al.   NEUROLOGY

Understanding immunosenescence to improve responses to vaccines

(2013) Jörg J Goronzy et al.   NATURE IMMUNOLOGY

Progressive multiple sclerosis: pathology and pathogenesis

(2012) Hans Lassmann et al.   Nature Reviews Neurology

Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans

(2012) Rafael Solana et al.   SEMINARS IN IMMUNOLOGY

Multiple Sclerosis in the Elderly Patient

(2010) Amer Awad et al.   DRUGS & AGING

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

(2009) Roisín Lonergan et al.   Multiple Sclerosis Journal

Relapses in multiple sclerosis are age- and time-dependent

(2008) H Tremlett et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY